Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We welcome the Association of Supportive and Palliative Care Pharmacy’s (ASPCP) recent position statement that the perceived benefit of the anticipatory prescribing of a syringe pump (driver) does not outweigh potential risks.1 This is an area of practice which has needed clear national guidance for some time.2 The committee cited the following specific risks: - A lack of individualisation. - No anticipation of dose/drug changes between prescribing and initiation. - Administration errors. Given these risks, it is of concern that anticipatory syringe pump prescribing appears relatively common in some areas of the UK and is perhaps increasing during the COVID-19 pandemic.

More information Original publication

DOI

10.1136/bmjspcare-2020-002735

Type

Other

Publisher

BMJ: Online first

Publication Date

19/01/2021

Addresses

Letter